The treatment patterns identified for T2DM, prioritizing metformin and DPP4 inhibitors far ahead of GLP-1 RA and insulin, align with therapeutic management recommendations for elderly patients [58,59,60] and are similar (26.4% of patients treated with oral antidiabetics and 5.2% with insulin) to those reported in the previous referred PYCAF study (24.6% and 7.4%, respectively) [45]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.